177 related articles for article (PubMed ID: 35683612)
21. Pathological and molecular biological approaches to early mesothelioma.
Tsujimura T; Torii I; Sato A; Song M; Fukuoka K; Hasegawa S; Nakano T
Int J Clin Oncol; 2012 Feb; 17(1):40-7. PubMed ID: 22237727
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
23. Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations.
Matsumoto S; Hamasaki M; Kinoshita Y; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2019 Nov; 69(11):637-645. PubMed ID: 31580004
[TBL] [Abstract][Full Text] [Related]
24. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
25. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
26. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
[TBL] [Abstract][Full Text] [Related]
27. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
Bueno R; Reblando J; Glickman J; Jaklitsch MT; Lukanich JM; Sugarbaker DJ
Ann Thorac Surg; 2004 Nov; 78(5):1774-6. PubMed ID: 15511473
[TBL] [Abstract][Full Text] [Related]
28. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
29. Malignant pleural mesothelioma presenting as a spontaneous pneumothorax.
Mitsui A; Saji H; Shimmyo T; Mochizuki A; Kurimoto N; Nakamura H
Respirol Case Rep; 2015 Mar; 3(1):9-12. PubMed ID: 25802741
[TBL] [Abstract][Full Text] [Related]
30. The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
Alì G; Bruno R; Fontanini G
J Thorac Dis; 2018 Jan; 10(Suppl 2):S276-S284. PubMed ID: 29507796
[TBL] [Abstract][Full Text] [Related]
31. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
32. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Cortes-Dericks L; Schmid RA
Respir Res; 2017 Apr; 18(1):58. PubMed ID: 28403901
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
34. Pleural neoplastic pathology.
Karpathiou G; Stefanou D; Froudarakis ME
Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases.
Barbieri PG; Consonni D; Schneider M
Tumori; 2022 Feb; 108(1):26-32. PubMed ID: 33719756
[TBL] [Abstract][Full Text] [Related]
36. [Current problems in the diagnosis of malignant pleural mesothelioma].
Hosokawa Y; Matsuge S; Hayashi K; Tao Y; Nakno R; Kemmochi Y; Ishimine A; Murakami Y; Kano S
Kyobu Geka; 2007 Jan; 60(1):14-8. PubMed ID: 17249532
[TBL] [Abstract][Full Text] [Related]
37. [Malignant pleural mesothelioma: diagnosis and treatment].
Delourme J; Dhalluin X; Cortot AB; Lafitte JJ; Scherpereel A
Rev Pneumol Clin; 2013 Feb; 69(1):26-35. PubMed ID: 23333048
[TBL] [Abstract][Full Text] [Related]
38. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
39. A Rare Case of Malignant Pleural Mesothelioma in a Young Healthy Male Without Asbestos Exposure.
Khatib S; Asad O; Asad H; Sabobeh T
Cureus; 2021 Aug; 13(8):e17199. PubMed ID: 34540427
[TBL] [Abstract][Full Text] [Related]
40. Genomic Deletion of
Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
